References
- Arnal C, Piette JC, Leon J, Taillan B, Hachulla E, Roudot-Thoraval F. Treatment of severe immune thrombocytopenia asso-ciated with systemic lupus erythematosus: 59 cases. J Ftheumatol 2002;29: 75–83.
- Tan EM, Cohen AS, Fries JI, Masi AT, Mcshane DJ, Rothfield NF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
- Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. Arthritis Rheum 1992;35:630–40.
- Imbach P, Barandim S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory in particular idiopathic thrombocytopenia in childhood. Hely Pediatr Acta 1981;46:81–6.
- Imbach P, Barandum S, d'Apuzzo V, Baumgartner C, Hirt A, More11 A, et al. High-dose intravenous gammaglobulin for idio-pathic thrombocytopenic purpura in childhood. Lancet 1981;2: 1228–31.
- Schmidt RE, Budde U, Schafer G, Stroehumann I. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic pur-pura. Lancet 1981;1:475–6.
- Yasunaga K, Uchino H, Akatsuka J. Assessment of high-dose immunoglobulin therapy in patients with advanced idiopathic thrombocytopenic purpura. Naika Hokan 1985;32:121–39.
- Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globurin dose but independent of salicylate dose. J Pediatr 1997;131:888–93.
- Mori M, Miyamae T, Imagawa T, Katakura S, Kimura K, Yokota S. Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Mod Ftheumatol 2004;14:361–6.
- Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A control trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 2000;329:1993–2000.
- Genevay S, Saudan-Kister A, Guerne P-A. Intravenous gammaglobulins in refractory polymyositis: lower dose for mainte-nance treatment is effective. Ann Rheum Dis 2001;60:635–6.
- Cherin P, Pelletier S, Teixeira A. Results and long-term follow-up of intravenous immunoglobulin infusion in chronic refractory poly-myositis. Arthritis Rheum 2002;46:467–74.
- Franconi C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long term IN. Ig treatment in systemic lupus erythematosus. Chin Exp Ftheumatol 1994;12:163–8.
- Heyneman CA, Gudger CA, Beckwith JV. Intravenous immune globulin for inducing remissions in systemic lupus erythematosus. Ann Pharmacother 1997;31:242–4.
- Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999;8:705–12.
- Karnali S, Celle A, Sayarlioglu M, Gul A, Inane M, Ocal L, et al. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Ftheumatol Int 2005;25:211–4.
- Schroeder JO, Zeuner RA, Euler HH, Loftier H. High dose intra-venous immunoglobulins in systemic lupus erythematosus: clin-ical and serological results of a pilot study. J Ftheumatol 1996;23: 71–5.
- Boletis JN, Loannidis JPA, Boki KA, Moutsopoulos HM. Intrave-nous immunoglobulin compared with cyclophosphamide for prolif-erative lupus nephritis. Lancet 1999;354:569–70.
- Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus. J Dermatol Treat 2004;15:46–50.
- Ballow M. Mechanisms of action of intravenous immunoglobulin: clinical implications in autoimmune and inflammatory diseases. In: Kazatchkine MD, Morell A, editors. Intravenous immunoglobulin research and therapy. New York: Parthenon; 1996. p. 123–8.
- Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activ-ity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484–6.